Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib in Advanced Hepatocellular Carcinoma
NCT03245190Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Apr 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chiauranib in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc. Primary endpoint: 16 weeks progression-free rate. Started Apr 2018; status: completed.
02
Drugs
chiauranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03245190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245190.